CIPRO TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE)

から入手可能:

BAYER INC

ATCコード:

J01MA02

INN（国際名）:

CIPROFLOXACIN

投薬量:

750MG

医薬品形態:

TABLET

構図:

CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 750MG

投与経路:

ORAL

パッケージ内のユニット:

50/100

処方タイプ:

Prescription

治療領域:

QUINOLONES

製品概要:

Active ingredient group (AIG) number: 0123207002; AHFS:

認証ステータス:

CANCELLED POST MARKET

承認日:

2018-12-10

製品の特徴

_CIPRO_
_®_
_ and CIPRO_
®
_ ORAL SUSPENSION_
Page 1 of 58
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
CIPRO
®
(Ciprofloxacin tablet USP)
250 mg, 500 mg, 750 mg
PR
CIPRO
® ORAL SUSPENSION
(Ciprofloxacin oral suspension)
10 g/100 mL
Antibacterial Agent
Manufactured by:
Bayer Inc.
2920 Matheson Boulevard East
Mississauga, Ontario
L4W 5R6
www.bayer.ca
Date of Revision:
February 18, 2020
Submission Control No: 233351
© 2020, Bayer Inc.
® TM see www.bayer.ca/tm-mc
All other trademarks are the property of their respective owners.
_CIPRO_
_®_
_ and CIPRO_
®
_ ORAL SUSPENSION_
Page 2 of 58
TABLE OF CONTENTS
PART
I:
HEALTH
PROFESSIONAL
INFORMATION ..........................................................
3
SUMMARY PRODUCT INFORMATION
...................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................
3
CONTRAINDICATIONS
..............................................................................................................
7
WARNINGS AND PRECAUTIONS
.............................................................................................
8
ADVERSE REACTIONS
.............................................................................................................
14
DRUG INTERACTIONS
.............................................................................................................
17
DOSAGE AND ADMINISTRATION
.........................................................................................
22
OVERDOSAGE
...........................................................................................................................
25
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................
26
STORAGE AND STABILITY
.....................................................................................................
28
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................